UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

Oncotarget, 2017-12, Vol.8 (67), p.111246-111257

2017

Volltextzugriff (PDF)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

JTO clinical and research reports, 2024-06, Vol.5 (6), p.100686, Article 100686

2024

Volltextzugriff (PDF)

Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors

Translational oncology, 2024-01, Vol.39, p.101834-101834, Article 101834

2024

Volltextzugriff (PDF)

Site-specific insertion of endonuclease recognition sites into amplicons to improve post-PCR analysis sensitivity of gene mutation

Biosensors & bioelectronics, 2022-07, Vol.208, p.114191-114191, Article 114191

2022

Volltextzugriff (PDF)

Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report

World journal of clinical cases, 2022-02, Vol.10 (6), p.1883-1888

2022

Volltextzugriff (PDF)

Label/Quencher-Free Detection of Exon Deletion Mutation in Epidermal Growth Factor Receptor Gene Using G-Quadruplex-Inducing DNA Probe

Journal of Microbiology and Biotechnology, 2017, 27(1), , pp.72-76

2017

Volltextzugriff (PDF)

A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma

Translational lung cancer research, 2022-02, Vol.11 (2), p.238-249

2022

Volltextzugriff (PDF)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Frontiers in medicine, 2023-06, Vol.10, p.1168220

2023

Volltextzugriff (PDF)

Non-small-cell lung cancer: how to manage EGFR-mutated disease

Drugs in context, 2022-08, Vol.11

2022

Volltextzugriff (PDF)

Label/Quencher-Free Detection of Exon Deletion Mutation in Epidermal Growth Factor Receptor Gene Using G-Quadruplex-Inducing DNA Probe

Journal of microbiology and biotechnology, 2017-01, Vol.27 (1), p.72-76

2017

Volltextzugriff (PDF)

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100624-100624, Article 100624

2024

Volltextzugriff (PDF)

Brain metastases in patients with non-small cell lung cancer: the role of mutated- EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination

Oncotarget, 2017-08, Vol.8 (32), p.53405-53418

2017

Volltextzugriff (PDF)

EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma

OncoTargets and therapy, 2017-01, Vol.10, p.4607-4613

2017

Volltextzugriff (PDF)

EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

American journal of clinical oncology, 2018-04, Vol.41 (4), p.385-390

2018

Volltextzugriff (PDF)

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements

Translational lung cancer research, 2016-06, Vol.5 (3), p.331-337

Costa, Daniel B.

2016

Volltextzugriff (PDF)

EGFR-TKI Sensitizing Mutation Rate in Adenocarcinoma of Lung

Pakistan Armed Forces medical journal, 2023-08, Vol.73 (SUPPL-1), p.S270-273

2023

Volltextzugriff (PDF)

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2022-07, Vol.119 (30), p.1-e2206588119

2022

Volltextzugriff (PDF)

The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis

Journal of thoracic disease, 2018-04, Vol.10 (4), p.2311-2320

2018

Volltextzugriff (PDF)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

BMC cancer, 2020-02, Vol.20 (1), p.103-103, Article 103

2020

Volltextzugriff (PDF)

次世代シークエンスを用いて検出したEGFR mutation L747P肺腺癌の1例

日本内科学会雑誌, 2023/01/10, Vol.112(1), pp.77-83

2023

Volltextzugriff (PDF)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer

Translational lung cancer research, 2020-08, Vol.9 (4), p.1149-1158

2020

Volltextzugriff (PDF)

EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC

International journal of molecular sciences, 2022-11, Vol.23 (21), p.13451

2022

Volltextzugriff (PDF)

Subtype of EGFR exon 19 deletion mutations

Translational lung cancer research, 2024-01, Vol.13 (1), p.195-198

Fujimoto, Nobukazu

2024

Volltextzugriff (PDF)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

Translational lung cancer research, 2020-06, Vol.9 (3), p.471-483

2020

Volltextzugriff (PDF)

Insertion sur l’exon 19 de l’EGFR : une mutation rare conférant une sensibilité à l’erlotinib ; à propos d’un cas d’adénocarcinome bronchique de stade IV et revue de la littérature

Revue des maladies respiratoires, 2019-05, Vol.36 (5), p.644-645

2019

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors

Site-specific insertion of endonuclease recognition sites into amplicons to improve post-PCR analysis sensitivity of gene mutation

Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report

Label/Quencher-Free Detection of Exon Deletion Mutation in Epidermal Growth Factor Receptor Gene Using G-Quadruplex-Inducing DNA Probe

A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

Non-small-cell lung cancer: how to manage EGFR-mutated disease

Label/Quencher-Free Detection of Exon Deletion Mutation in Epidermal Growth Factor Receptor Gene Using G-Quadruplex-Inducing DNA Probe

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Brain metastases in patients with non-small cell lung cancer: the role of mutated- EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination

EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma

EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements

EGFR-TKI Sensitizing Mutation Rate in Adenocarcinoma of Lung

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

次世代シークエンスを用いて検出したEGFR mutation L747P肺腺癌の1例

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer

EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC

Subtype of EGFR exon 19 deletion mutations

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

Insertion sur l’exon 19 de l’EGFR : une mutation rare conférant une sensibilité à l’erlotinib ; à propos d’un cas d’adénocarcinome bronchique de stade IV et revue de la littérature

Aktive Filter

Suchergebnisse filtern